Guideline Concordance of Treatment and Outcomes Among Adult Non-Hodgkin Lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort
The Oncologist · 02.11.2023 · 28 (11) · e1017-e1030
DOI: 10.1093/oncolo/oyad157 ↗Kurz gefasst
Leitlinie in der Zeitschrift The Oncologist, online erschienen am 27.06.2023. Verfasst von Nikolaus Christian Simon Mezger und 23 weiteren Autor:innen. Beteiligte Einrichtung: Global Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle, Germany. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Cancer Society, German Ministry for Economic and Development Cooperation, German International Cooperation.
Abstract (Originalsprache)
Background
Although non-Hodgkin lymphoma (NHL) is the 6th most common malignancy in Sub-Saharan Africa (SSA), little is known about its management and outcome. Herein, we examined treatment patterns and survival among NHL patients.
Methods
We obtained a random sample of adult patients diagnosed between 2011 and 2015 from 11 population-based cancer registries in 10 SSA countries. Descriptive statistics for lymphoma-directed therapy (LDT) and degree of concordance with National Comprehensive Cancer Network (NCCN) guidelines were calculated, and survival rates were estimated.
Findings
Of 516 patients included in the study, sub-classification was available for 42.1% (121 high-grade and 64 low-grade B-cell lymphoma, 15 T-cell lymphoma and 17 otherwise sub-classified NHL), whilst the remaining 57.9% were unclassified. Any LDT was identified for 195 of all patients (37.8%). NCCN guideline-recommended treatment was initiated in 21 patients. This corresponds to 4.1% of all 516 patients, and to 11.7% of 180 patients with sub-classified B-cell lymphoma and NCCN guidelines available. Deviations from guideline-recommended treatment were initiated in another 49 (9.5% of 516, 27.2% of 180). By registry, the proportion of all patients receiving guideline-concordant LDT ranged from 30.8% in Namibia to 0% in Maputo and Bamako. Concordance with treatment recommendations was not assessable in 75.1% of patients (records not traced (43.2%), traced but no sub-classification identified (27.8%), traced but no guidelines available (4.1%)). By registry, diagnostic work-up was in part importantly limited, thus impeding guideline evaluation significantly. Overall 1-year survival was 61.2% (95%CI 55.3%-67.1%). Poor ECOG performance status, advanced stage, less than 5 cycles and absence of chemo (immuno-) therapy were associated with unfavorable survival, while HIV status, age, and gender did not impact survival. In diffuse large B-cell lymphoma, initiation of guideline-concordant treatment was associated with favorable survival.
Interpretation
This study shows that a majority of NHL patients in SSA are untreated or undertreated, resulting in unfavorable survival. Investments in enhanced diagnostic services, provision of chemo(immuno-)therapy and supportive care will likely improve outcomes in the region.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Global Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
- African Cancer Registry Network, Oxford, UK.
- Nuffield Department of Population Health, University of Oxford, Oxford, UK.
- Dr AB May Cancer Care Centre, Windhoek, Namibia.
- Registre des cancers de Brazzaville, Brazzaville, Republic of the Congo.
- Division of Hematology, Department of Internal Medicine, University and Black Lion Hospital, Addis Ababa, Ethiopia.
ORCID-Profile: Nikolaus Christian Simon Mezger, Ahmedin Jemal, Eva Johanna Kantelhardt
Förderung
- American Cancer Society
- German Ministry for Economic and Development Cooperation
- German International Cooperation
Zitieren
APA
Mezger, N. C. S., Hämmerl, L., Griesel, M., Seraphin, T. P., Joko-Fru, Y. W., Feuchtner, J., Zietsman, A., Péko, J. F., Tadesse, F., Buziba, N. G., Wabinga, H., Nyanchama, M., Chokunonga, E., Kéita, M., N'da, G., Lorenzoni, C. F., Akele-Akpo, M. T., Mezger, J. M., Binder, M., …, & Kantelhardt, E. J. (2023). Guideline Concordance of Treatment and Outcomes Among Adult Non-Hodgkin Lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort. The Oncologist, 28(11), e1017-e1030. https://doi.org/10.1093/oncolo/oyad157
Vancouver
Mezger NCS, Hämmerl L, Griesel M, Seraphin TP, Joko-Fru YW, Feuchtner J, et al. Guideline Concordance of Treatment and Outcomes Among Adult Non-Hodgkin Lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort. The Oncologist. 2023;28(11):e1017-e1030. doi:10.1093/oncolo/oyad157
BibTeX
@article{Mezger2023,
author = {Mezger, Nikolaus Christian Simon and Hämmerl, Lucia and Griesel, Mirko and Seraphin, Tobias Paul and Joko-Fru, Yvonne Walburga and Feuchtner, Jana and Zietsman, Annelle and Péko, Jean-Félix and Tadesse, Fisihatsion and Buziba, Nathan Gyabi and Wabinga, Henry and Nyanchama, Mary and Chokunonga, Eric and Kéita, Mamadou and N'da, Guy and Lorenzoni, Cesaltina Ferreira and Akele-Akpo, Marie-Thérèse and Mezger, Jörg Michael and Binder, Mascha and Liu, Biying and Bauer, Marcus and Henke, Oliver and Jemal, Ahmedin and Kantelhardt, Eva Johanna},
title = {Guideline Concordance of Treatment and Outcomes Among Adult Non-Hodgkin Lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort},
journal = {The Oncologist},
year = {2023},
volume = {28},
number = {11},
pages = {e1017--e1030},
doi = {10.1093/oncolo/oyad157}
}
EUVIMED